Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency

Participants in the study group will receive a single bolus of Sugammadex (4.0mg/kg) prior to extubation. In the post-anesthesia care unit (PACU), a blinded safety-assessor will use the visual analog scale to clinically assess post-operative pain. Post-operative nausea and vomiting (PONV) will be assessed using a PONV rating scale every 30 minutes until PACU discharge. All patients will be monitored with continuous pulse-oximetry.

Inclusion criteria

• Patients scheduled for open ventral hernia repair or open colectomy
• ASA class I-III
• 18 years and older
• Subjects with a body mass index (BMI) of <45kg/m2 and weight less than 150kg
• Subjects who have given written informed consent

Exclusion criteria

• Subjects with medical conditions and/or undergoing surgical procedures that are not compatible with the use of the TOF-Watch® SX (e.g., injuries to the thumbs/distal forearms, bilateral ulnar nerve damage or subjects with cardiac pacemaker
• Subjects known or suspected to have neuromuscular disorders impairing neuromuscular blockade (e.g., subjects with myasthenia gravis)
• Subjects known or suspected to have significant renal dysfunction (e.g. creatinine clearance < 30 mL.min-1
• Subjects known or suspected to have a (family)history of malignant hyperthermia; have significant hepatic dysfunction
• Subjects known or suspected to have an allergy to opiates/opioids, muscle relaxants or other medications used during general anesthesia;
• Subjects known or suspected to be hypersensitive to Sugammadex or other cyclodextrins or Rocuronium or any of its excipients
• Subjects who have a contraindication to, Rocuronium or Sugammadex
• Female subjects who are pregnant
• Morbidly obese subjects with a BMI > 45 kg/m2 or weight more than 150 kg